Methods for use with BAFF antagonists

US8617545B2 · kind B2 · utility

Assignees

• BIOGEN IDEC MA INC. · US
• Genentech, Inc. · US

Inventors

• Yen-Ming Hsu · Lexington, US
• Leonid Gorelik · Newton, US
• Tatiana Novobrantseva · Cambridge, US
• Joanne Quan · San Francisco, US
• Flavius Martin · Hayward, US
• Susan L. Kalled · Concord, US

Key dates

• Filing date: Oct 12, 2006
• Grant date: Dec 31, 2013
• Expiry date: May 14, 2029

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

BAFF plays a central role in acquired immunity. The disclosure identifies BAFF-responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by treatment with a BAFF antagonist. Specific genes are: NF-κB2, CD23, H2-Mβ (the beta chain of H2-DM), Fig-1, and OBF-1. The disclosure provides methods and compositions for: monitoring the activity of a BAFF antagonist in a mammal; monitoring BAFF activity in a mammal; identifying a mammal to be treated with a BAFF antagonist; and related uses. Such methods include detecting one or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-Mβ molecule in a biological sample of the mammal, and optionally further detecting NF-κB2 molecule and/or CD23 molecule in the biological sample.